Development of Imvax’s IGV-001 for the Treatment of Newly Diagnosed Glioblastoma Utilizes a Personalized Tumor-Derived Immunotherapy Platform Exploiting the Full Antigenic Signature of GBM

Time: 11:00 am
day: Conference Day 2


  • IGV-001, an autologous cell Immunotherapy with antisense oligonucleotide (IMV-001) targeting IGF1R, is a biologic-device combination product developed from Imvax’s proprietary platform, GoldspireTM
  • Imvax’s GBM program builds on published Phase 1b data to leverage this cell-based autologous immunotherapy to combat the immunosuppressive GBM TME
  • A randomized, multicenter, double-blind, placebo-controlled, Phase 2b study assessing the safety and efficacy of IGV-001 in newly diagnosed patients with glioblastoma enrolled the first patient in March 2023
  • The Phase 2b trial will enroll up to 93 participants in a 2:1 randomization across approximately 25 sites in the U.S. and is on schedule to complete enrollment in the first half of 2024
  • The primary endpoint of the study is median progression-free survival (PFS) and key secondary endpoints include overall survival and safety, with PFS data expected to be available in mid-2025